ETNB To Report ENTRIGUE Data In Q2, MDVL's Q1 Revenue To More Than Double, OCUP On Watch

Landos Biopharma Inc. (LABP) expects to initiate a phase 2b study of Omilancor in ulcerative colitis later this year. NX-13, for the potential treatment of Ulcerative Colitis, and LABP-104, for the potential treatment of systemic lupus erythematosus and/or rheumatoid arthritis, are the other investigational drugs in the pipeline

from RTT - Top Story https://ift.tt/3Jp4U7n
via IFTTT